Drugs.com - Clinical TrialsThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. Subscribe to this data using MyMedWorm.Subscribe to this data using GoogleReader.Subscribe to this data using Bloglines.Subscribe to this data using MyYahoo.

This page shows you the latest items in this publication.

Pages: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30

5587 records returned

Genasense Given as High-Dose IV Infusion with Chemotherapy Shows Promising Activity in Advanced MelanomaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Data Presented at International Melanoma Conference in Berlin Results Follow Decision by Company to Continue Phase 3 AGENDA Trial for Overall Survival BERKELEY HEIGHTS, N.J.--(BUSINESS WIRE)--Nov 20, 2009 - Genta Incorporated (OTCBB:... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 20, 2009 Category: Pharmaceuticals Source Type: clinical trials

Ligand Presents New Preclinical Data on its Lead SARM Molecule LGD-4033 at the Gerontological Society of America Annual MeetingEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
SAN DIEGO--(BUSINESS WIRE)--Nov 20, 2009 - Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that data from a preclinical study on its selective androgen receptor modulator (SARM) LGD-4033 was featured in a poster presentation at... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 20, 2009 Category: Pharmaceuticals Source Type: clinical trials

Inovio Biomedical Universal Flu Vaccines Demonstrate Broadly Protective Immune Responses Against Multiple Seasonal & Pandemic Influenza Viruses in Pre-Clinical StudiesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Inovio's SynConTM Universal Flu Vaccines Provide 100% Protection in Ferrets against Death and Sickness in a Challenge Study with the Pandemic H1N1 Virus SAN DIEGO--(BUSINESS WIRE)--Nov 20, 2009 - Inovio Biomedical Corporation (NYSE Amex:INO), a... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 20, 2009 Category: Pharmaceuticals Source Type: clinical trials

Military Study Shows Prevention of Novel A/H1N1 Virus Infection is Vaccine-Type and Age-DependentEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Both Live, Attenuated Influenza Vaccine (LAIV) and Trivalent Inactivated Vaccine (TIV) provide Protection against novel A/H1N1, especially against severe disease WASHINGTON, Nov. 19 /PRNewswire/ -- Immunization with either live attenuated influenza... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 19, 2009 Category: Pharmaceuticals Source Type: clinical trials

Positive Results from Chronic Study with Bayer ?s Rivaroxaban Will be Presented As a Late Breaker at ASH 2009Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Positive Results from Chronic Study with Bayer’s Rivaroxaban Will be Presented As a Late Breaker at ASH 2009 Endpoints met in EINSTEIN-Extension Trial in the Secondary Prevention of Recurrent Symptomatic VTE Berlin, November 19, 2009 -... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 19, 2009 Category: Pharmaceuticals Source Type: clinical trials

VIVUS Announces Positive Results From Phase 3 Study of Avanafil in Erectile Dysfunction; Data Demonstrate Robust Efficacy, Favorable Side-Effect ProfileEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Results Underscore Differentiating Profile; Indicate Significant Market Opportunity for Avanafil MOUNTAIN VIEW, Calif., Nov. 18 /PRNewswire-FirstCall/ -- VIVUS, Inc. (NASDAQ:VVUS) today announced positive results from REVIVE (TA-301), a phase 3... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 19, 2009 Category: Pharmaceuticals Source Type: clinical trials

Epiphany Announces Positive Results from Its Phase 2b Trial in Shingles.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
SAN FRANCISCO, Nov. 18 /PRNewswire/ -- Epiphany Biosciences announced results from its Phase 2b dose-ranging study of EPB-348 (valomaciclovir) in patients with shingles (herpes zoster) infection. The study's primary endpoint was non-inferiority... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 19, 2009 Category: Pharmaceuticals Source Type: clinical trials

ImmuPharma announces Positive Ph2b Lupuzor trial resultsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
ENCOURAGING FINAL PHASE IIb RESULTS SEEN WITH LUPUZOR™ IN SYSTEMIC LUPUS ERYTHEMATOSUS ~ Greatest benefits seen in patients with moderate to severe Systemic Lupus Erythematosus ~ LONDON, Nov. 19, 2009-ImmuPharma PLC (LSE: IMM) the... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 19, 2009 Category: Pharmaceuticals Source Type: clinical trials

Basilea presents new research data on oncology drug candidate BAL27862 at international cancer conferenceEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Basel, Switzerland, November 19, 2009 - Basilea Pharmaceutica Ltd. (SIX:BSLN) presents new research data on its innovative antitumor drug candidate BAL27862 at the international conference on Molecular Targets and Cancer Therapeutics in Boston... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 19, 2009 Category: Pharmaceuticals Source Type: clinical trials

Medivir: Epiphany Biosciences Announces Positive Results from Its Phase 2b Trial in ShinglesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
STOCKHOLM--(BUSINESS WIRE)--Nov 19, 2009 - Regulatory News: Medivir (STO:MVIRB): The Epiphany Biosciences press release reads as follows; Epiphany Biosciences announced results from its Phase 2b dose-ranging study of EPB-348 (valomaciclovir)... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 19, 2009 Category: Pharmaceuticals Source Type: clinical trials

Geron Presents Interim Clinical Data on Its Telomerase Inhibitor Drug at AACR-NCI-EORTCEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Dosing Schedule of Imetelstat Achieves Drug Exposure Consistent with In Vivo Inhibition of Tumor Growth MENLO PARK, Calif.--(BUSINESS WIRE)--Nov 19, 2009 - Geron Corporation (Nasdaq:GERN) today announced the presentation of interim data from its... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 19, 2009 Category: Pharmaceuticals Source Type: clinical trials

Synta Presents Preclinical Data on Next Generation Hsp90 Inhibitor, STA-9090Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
- Broad anti-cancer activity as a single agent and in combination - Strong potency against highly resistant cancers - Superior profile to first generation Hsp90 inhibitors LEXINGTON, Mass.--(BUSINESS WIRE)--Nov 18, 2009 -... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 18, 2009 Category: Pharmaceuticals Source Type: clinical trials

Synta Presents New Data on Mechanism of Action of Elesclomol at AACR-NCI-EORTC Conference on Molecular Targets and Cancer TherapeuticsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Copper redox reaction key to elesclomol's ability to generate ROS LEXINGTON, Mass.--(BUSINESS WIRE)--Nov 18, 2009 - Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 18, 2009 Category: Pharmaceuticals Source Type: clinical trials

Sangamo BioSciences Provides Update on Phase 1 Safety Trial of SB-728-T for HIV/AIDSEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
RICHMOND, Calif., Nov. 18 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (NASDAQ:SGMO) announced today that data from the University of Pennsylvania investigator sponsored Phase 1 safety study of Sangamo's zinc finger nuclease (ZFN) based... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 18, 2009 Category: Pharmaceuticals Source Type: clinical trials

Results From Two Phase II Trials Add to Understanding of Ticagrelor (BRILINTA(TM)) and How it Works in the BodyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Ticagrelor data presented at the American Heart Association Scientific Sessions ORLANDO, Fla., Nov. 18 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE:AZN) today announced the results of the phase II studies, ONSET/OFFSET and RESPOND for... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 18, 2009 Category: Pharmaceuticals Source Type: clinical trials

Peregrine Pharmaceuticals Presents Promising Antiviral Data at 2009 Chemical and Biological Defense Science & Technology ConferenceEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
- In Preclinical Studies, Peregrine's PS-Targeting Antibodies Including Bavituximab Demonstrated Broad Spectrum Binding to Viruses and Virally Infected Cells Representing Three Viral Hemorrhagic Fever (VHF) Families - - Preclinical Efficacy... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 18, 2009 Category: Pharmaceuticals Source Type: clinical trials

Exelixis Reports Encouraging Phase 1 Data for the PI3K Inhibitor Xl147 (SAR245408) in Combination with Erlotinib at the AACR-NCI-EORTC ConferenceEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
BOSTON--(BUSINESS WIRE)--Nov 18, 2009 - Exelixis, Inc. (Nasdaq:EXEL) today reported interim data from an ongoing phase 1 dose-escalation trial of XL147 (SAR245408) in combination with the EGFR inhibitor erlotinib in patients with advanced solid... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 18, 2009 Category: Pharmaceuticals Source Type: clinical trials

Cardiovascular Outcomes with Ezetimibe and Simvastatin Similar to Statin Alone, Claims Data SuggestEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Retrospective Analysis of Almost 30,000 Patients Shows No Significant Difference in Risk of Heart Attack or Stroke with Monotherapy Compared With Combination Therapy IRVINE, Calif.--(BUSINESS WIRE)--Nov 18, 2009 - Prescription Solutions, a leading... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 18, 2009 Category: Pharmaceuticals Source Type: clinical trials

Zydena is Efficacious in Once Daily Dosing for Erectile Dysfunction/Positive BPH ResultsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Data to be presented at 12th Congress of the European Society for Sexual Medicine, November 15th to 18th, Lyon SEOUL, South Korea, Nov. 18 /PRNewswire/ -- Dong-A Pharmaceutical Co., Ltd. and Dong-A PharmTech, Co. Ltd. announced today that it has... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 18, 2009 Category: Pharmaceuticals Source Type: clinical trials

Threshold Pharmaceuticals Presents Interim Prostate Cancer Data From Early Stage Trials of TH-302Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Threshold Pharmaceuticals Presents Interim Prostate Cancer Data From Early Stage Trials of TH-302 REDWOOD CITY, Calif., Nov. 18, 2009 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today announced clinical trial results related to... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 18, 2009 Category: Pharmaceuticals Source Type: clinical trials

Viron reports positive Phase II data in Acute Coronary Syndromes (ACS) patientsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
VT-111 significantly reduces key cardiac enzymes at multiple time points after stent placement; Data presented at American Heart Association 2009 Scientific Sessions LONDON, ON, Nov. 18 /PRNewswire/ -- Viron Therapeutics Inc., a biotechnology... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 18, 2009 Category: Pharmaceuticals Source Type: clinical trials

Genzyme Announces Results of Phase 2/3 Trial of Advanced Phosphate BinderEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CAMBRIDGE, Mass., Nov. 18, 2009-Genzyme Corporation (Nasdaq: GENZ) today reported results of a phase 2/3 study of its advanced phosphate binder (APB). The trial met its primary endpoint, which was to show that the APB lowered phosphate levels... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 18, 2009 Category: Pharmaceuticals Source Type: clinical trials

ImmunoGen Announces Encouraging Clinical Data with Its IMGN901 Compound in the Treatment of Merkel Cell CarcinomaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
WALTHAM, MA, November 17, 2009 – ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics, today reported encouraging clinical data with its IMGN901 product candidate in the treatment of Merkel... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 18, 2009 Category: Pharmaceuticals Source Type: clinical trials

Results From Phase 2b Study on Atrial Fibrillation Agent Reviewed at American Heart AssociationEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
FREMONT, Calif., Nov 18, 2009 (BUSINESS WIRE) -- ARYx Therapeutics, Inc. (NASDAQ:ARYX), a biopharmaceutical company, announced that a review of the results of the Phase 2b clinical trial, PASCAL, testing the efficacy and safety of ARYx's... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 18, 2009 Category: Pharmaceuticals Source Type: clinical trials

Alnylam Presents New Pre-clinical Data on ALN-VSP, an RNAi Therapeutic for the Treatment of Liver CancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
- New Results Demonstrate Robust Anti-Tumor Activity in Multiple Models, Including Extra-Hepatic Tumors - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov 18, 2009 - Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company,... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 18, 2009 Category: Pharmaceuticals Source Type: clinical trials

Genzyme Announces Results of Phase 2/3 Trial of Advanced Phosphate BinderEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov 18, 2009 - Genzyme Corporation (Nasdaq: GENZ) today reported results of a phase 2/3 study of its advanced phosphate binder (APB). The trial met its primary endpoint, which was to show that the APB... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 18, 2009 Category: Pharmaceuticals Source Type: clinical trials

YM Biosciences Reports Cyt997 Oral Vascular Disrupting Agent Results Presented At AACR-NCI-EORTC MeetingEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
MISSISSAUGA, ON, November 17, 2009 /PRNewswire-FirstCall/ - YM BioSciences Inc. , a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development,... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 17, 2009 Category: Pharmaceuticals Source Type: clinical trials

American Heart Association Late Breaking Clinical Trial Report: High Dose of Angiotensin Receptor Blockers Effective in Heart Failure PatientsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Study highlights: -- Iron treatment with intravenous (I.V.) ferric carboxymaltose significantly improved symptoms, functional capacity and quality of life for Class II and III chronic heart failure (CHF) patients. -- This treatment worked equally... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 17, 2009 Category: Pharmaceuticals Source Type: clinical trials

Semafore Pharmaceuticals Announces Phase I Data Presentation Highlighting Novel PI3K Pathway Inhibitor at 51st ASH Annual MeetingEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
INDIANAPOLIS--(BUSINESS WIRE)--Nov 16, 2009 - Researchers are scheduled to present Phase I data relating to Semafore Pharmaceuticals' lead product candidate, SF1126, as a treatment for patients with relapsed and refractory myeloma during the... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 17, 2009 Category: Pharmaceuticals Source Type: clinical trials

BioSante Pharmaceuticals Comments on Boehringer Ingelheim Clinical Test Results in Treatment of Female Sexual DysfunctionEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--Nov 16, 2009 - BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX), a specialty pharmaceutical company developing products for female sexual health, including LibiGel® for the treatment of hypoactive sexual desire... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 17, 2009 Category: Pharmaceuticals Source Type: clinical trials

Aegerion Pharmaceuticals Announces Additional Lomitapide (AEGR-733) Phase III Data Demonstrates Significant Lowering of LDL Cholesterol with Promising Safety ProfileEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Results Will Be Presented Today At AHA Conference in Orlando, Florida BRIDGEWATER, N.J.--(BUSINESS WIRE)--Nov 16, 2009 - Aegerion Pharmaceuticals, Inc., a biopharmaceutical company focused on the treatment of cardiovascular and metabolic... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 17, 2009 Category: Pharmaceuticals Source Type: clinical trials

Pluristem Therapeutics Announces Three Month Follow-Up Data from the First Patient to Receive PLX-PADEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Data Suggests PLX-PAD is Safe, with Noted Improvement in Measured Efficacy Parameters HAIFA, Israel--(BUSINESS WIRE)--Nov 17, 2009 - Pluristem Therapeutics Inc. (NasdaqCM:PSTI) (DAX:PJT) today announced that safety and potential efficacy... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 17, 2009 Category: Pharmaceuticals Source Type: clinical trials

Higher Dose of Merck's Cozaar (losartan potassium tablets) Significantly Reduced Deaths and Hospitalizations Due to Heart Failure In Investigational StudyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Results from HEAAL Study Presented as Late-Breaker at American Heart Association Scientific Sessions 2009 ORLANDO, Fla.--(BUSINESS WIRE)--Nov 17, 2009 - In an investigational study, Merck's medicine COZAAR (losartan potassium tablets) 150 mg,... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 17, 2009 Category: Pharmaceuticals Source Type: clinical trials

NeoPharm Presents the Phase I Data for Patients with Metastatic Solid TumorsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
LAKE BLUFF, Ill.--(BUSINESS WIRE)--Nov 17, 2009 - NeoPharm, Inc. (Other OTC: NEOL.PK) today announced the results of a Phase I clinical trial of Liposome Encapsulated Docetaxel (LE-DT) an active component of Taxotere® at a joint International... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 17, 2009 Category: Pharmaceuticals Source Type: clinical trials

Merck's Investigational Anacetrapib Phase IIb Study Results Presented at American Heart Association Annual Scientific SessionsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Persistent Lipid Effects Remained in the Higher Dose Arms After Cessation Of Therapy in Patients with Dyslipidemia ORLANDO, Fla.--(BUSINESS WIRE)--Nov 17, 2009 - In a phase IIb study in 589 patients with primary hypercholesterolemia or... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 17, 2009 Category: Pharmaceuticals Source Type: clinical trials

Interim Phase 2 Survival Data for PV-10 Will Be Presented by Professor John F. Thompson, MD, on November 21, 2009Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Lead Investigator for Provectus' PV-10 Trial Will Present At 3rd World Meeting of Interdisciplinary Melanoma/Skin Cancer Centers in Berlin Will Update Compassionate Use Program KNOXVILLE, Tenn.--(BUSINESS WIRE)--Nov 17, 2009 -... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 17, 2009 Category: Pharmaceuticals Source Type: clinical trials

Exelixis Reports Encouraging Phase 1 Data for the PI3K Inhibitor XL147 (SAR245408) in Combination with Paclitaxel and Carboplatin at the AACR-NCI-EORTC ConferenceEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
BOSTON--(BUSINESS WIRE)--Nov 17, 2009 - Exelixis, Inc. (Nasdaq:EXEL) today reported interim data from an ongoing phase 1 dose-escalation trial of XL147 (SAR245408) in combination with paclitaxel and carboplatin in patients with advanced solid... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 17, 2009 Category: Pharmaceuticals Source Type: clinical trials

ImmunoGen, Inc. Announces Encouraging Clinical Data with Its IMGN901 Compound in the Treatment of Merkel Cell CarcinomaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
WALTHAM, Mass.--(BUSINESS WIRE)--Nov 17, 2009 - ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics, today reported encouraging clinical data with its IMGN901 product candidate in the treatment... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 17, 2009 Category: Pharmaceuticals Source Type: clinical trials

AVEO's Triple VEGF Receptor Inhibitor Tivozanib in Combination with mTOR Inhibitor Demonstrates Anti-tumor Activity and Tolerability in Advanced Kidney Cancer; Preliminary Results Presented at AACR-NCI-EORTC MeetingEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Preclinical Combination Data Also Presented, Demonstrate mTOR-Tivozanib Combination in Breast Tumor Model Prevents Emergence of Resistance CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov 17, 2009 - AVEO Pharmaceuticals, Inc., a biopharmaceutical company... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 17, 2009 Category: Pharmaceuticals Source Type: clinical trials

Poniard Pharmaceuticals Announces Updated Positive Clinical Data from Phase 2 Trial of Picoplatin in Colorectal Cancer and New Phase 1 Cardiac Safety Trial ResultsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
- Data Presented at AACR-NCI-EORTC's "Molecular Targets and Cancer Therapeutics" International Conference - SOUTH SAN FRANCISCO, Calif., Nov. 17 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (NASDAQ:PARD) today announced updated... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 17, 2009 Category: Pharmaceuticals Source Type: clinical trials

American Heart Association Late Breaking Clinical Trial Report: Treatment for Iron Deficiency Improves Symptoms, Functional Capacity and Quality of Life in Chronic Heart Failure PatientsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Study highlights: -- Iron treatment with intravenous (I.V.) ferric carboxymaltose significantly improved symptoms, functional capacity and quality of life for Class II and III chronic heart failure (CHF) patients. -- This treatment worked equally... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 17, 2009 Category: Pharmaceuticals Source Type: clinical trials

Oncolytics Biotech Inc. Collaborators Present Positive Phase I/II Trial Results in Advanced Solid Cancers with a Focus on the Head and Neck at the AACR-NCI-EORTC MeetingEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CALGARY, Nov. 17 /PRNewswire-FirstCall/ -- Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced updated results from a Phase I/II U.K. trial (REO 011) of REOLYSIN(R) combined with paclitaxel/carboplatin for... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 17, 2009 Category: Pharmaceuticals Source Type: clinical trials

Data from Mipomersen Phase 3 Trial in hoFH Patients Presented at AHAEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Study Meets Primary Endpoint with 25 Percent LDL Reduction in Very High-Risk Patient Population CAMBRIDGE, Mass. & CARLSBAD, Calif.--(BUSINESS WIRE)--Nov. 17, 2009-- Genzyme Corp. (NASDAQ: GENZ) and Isis Pharmaceuticals Inc. (NASDAQ:... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 17, 2009 Category: Pharmaceuticals Source Type: clinical trials

Shire Announces Publication of Open-Label Study on Coadministration of INTUNIV (guanfacine) Extended-Release Tablets with StimulantsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 17, 2009 Category: Pharmaceuticals Source Type: clinical trials

The Medicines Company Announces Positive Phase III Data in Two Late-Breakers at AHA and in NEJMEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Data from Two International Trials with nearly 14,000 Patients Presented at American Heart Association Scientific Sessions and Published in Two Papers in the New England Journal of Medicine Parsippany, N.J., November 15, 2009—The Medicines... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 17, 2009 Category: Pharmaceuticals Source Type: clinical trials

Ticagrelor (BRILINTAT) Demonstrated Greater Efficacy Over Clopidogrel in the Most Urgent Clinical SettingEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Orlando, FL -November 15, 2009 – AstraZeneca (NYSE: AZN) today announced results of a PLATO sub-analysis in the most serious type of Acute Coronary Syndrome (ACS) patients, those with ST Segment Elevation Myocardial Infarction (STEMI).... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 17, 2009 Category: Pharmaceuticals Source Type: clinical trials

NicOx - NCX 6560 meets primary and secondary objectives in first-in-man studyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Sophia Antipolis, France, November 13, 2009 - NicOx S.A. (NYSE Euronext Paris: COX) today announced that a phase 1b, first-in-man study for NCX 6560, versus placebo and Lipitor® (atorvastatin), has met its primary and secondary objectives. The... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 17, 2009 Category: Pharmaceuticals Source Type: clinical trials

Novartis Influenza A(H1N1) 2009 vaccine US interim data show lower doses of antigen may suffice to generate a protective immune response against A(H1N1)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Interim clinical data from approximately 4,000 individuals suggest that half a dose of the currently US-approved Novartis unadjuvanted Influenza A(H1N1) 2009 vaccine met immunogenicity criteria in adults and the elderly Data also show that... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 17, 2009 Category: Pharmaceuticals Source Type: clinical trials

BioInvent and ThromboGenics Complete Phase I Patient Trial of Anti-PlGF Cancer Therapeutic TB-403 in Patients with Advanced Solid TumoursEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Lund, Sweden and Leuven, Belgium – 16 November 2009 – BioInvent International AB (OMXS: BINV) and ThromboGenics NV (Euronext Brussels: THR) today announced positive results from a Phase I trial of their novel anti-cancer monoclonal... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 16, 2009 Category: Pharmaceuticals Source Type: clinical trials

Gentium Announces Presentation of Defibrotide Clinical Data at the American Society of Hematology Annual MeetingEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
VILLA GUARDIA (COMO), Italy--(BUSINESS WIRE)--Nov 16, 2009 - Gentium S.p.A. (Nasdaq: GENT) announced today that results from the Company's Phase II/III Pediatric Prevention trial and Phase III Treatment trial for Defibrotide of Hepatic... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 16, 2009 Category: Pharmaceuticals Source Type: clinical trials